{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:48:50Z","timestamp":1792028930485,"version":"4.4.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s00213-015-4161-1","type":"journal-article","created":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T23:49:46Z","timestamp":1449013786000},"page":"741-750","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review"],"prefix":"10.1007","volume":"233","author":[{"given":"Christoffer","family":"Polcwiartek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmi","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,2]]},"reference":[{"key":"4161_CR1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.4306\/pi.2013.10.4.417","volume":"10","author":"Y Albayrak","year":"2013","unstructured":"Albayrak Y, Hashimoto K (2013) Benefical effects of sigma-1 agonist fluvoxamine for tardive dyskinesia and tardive akathisia in patients with schizophrenia: report of three cases. Psychiatry Investig 10:417\u2013420","journal-title":"Psychiatry Investig"},{"key":"4161_CR2","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.ftd.0000164609.14808.93","volume":"27","author":"G Bondolfi","year":"2005","unstructured":"Bondolfi G, Morel F, Crettol S, Rachid F, Baumann P, Eap CB (2005) Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther Drug Monit 27:539\u2013543","journal-title":"Ther Drug Monit"},{"key":"4161_CR3","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1176\/ajp.153.12.1625","volume":"153","author":"RW Buchanan","year":"1996","unstructured":"Buchanan RW, Kirkpatrick B, Bryant N, Ball P, Breier A (1996) Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am J Psychiatry 153:1625\u20131627","journal-title":"Am J Psychiatry"},{"key":"4161_CR4","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1440-1819.2004.01269.x","volume":"58","author":"W Chaichan","year":"2004","unstructured":"Chaichan W (2004) Olanzapine plus fluvoxamine and olanzapine alone for the treatment of an acute exacerbation of schizophrenia. Psychiatry Clin Neurosci 58:364\u2013368","journal-title":"Psychiatry Clin Neurosci"},{"key":"4161_CR5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s002130051036","volume":"145","author":"WH Chang","year":"1999","unstructured":"Chang WH, Augustin B, Lane HY, ZumBrunnen T, Liu HC, Kazmi Y, Jann MW (1999) In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine. Psychopharmacology 145:91\u201398","journal-title":"Psychopharmacology"},{"key":"4161_CR6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/00004714-199702000-00024","volume":"17","author":"SA Chong","year":"1997","unstructured":"Chong SA, Tan CH, Lee HS (1997) Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: two case reports. J Clin Psychopharmacol 17:68\u201369","journal-title":"J Clin Psychopharmacol"},{"key":"4161_CR7","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/01.jcp.0000116646.91923.2f","volume":"24","author":"CB Eap","year":"2004","unstructured":"Eap CB, Bender S, Jaquenoud Sirot E, Cucchia G, Jonzier-Perey M, Baumann P, Allorge D, Broly F (2004) Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol 24:214\u2013219","journal-title":"J Clin Psychopharmacol"},{"key":"4161_CR8","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/00004714-200012000-00024","volume":"20","author":"M Fabrazzo","year":"2000","unstructured":"Fabrazzo M, La Pia S, Monteleone P, Mennella R, Esposito G, Pinto A, Maj M (2000) Fluvoxamine increases plasma and urinary levels of clozapine and its major metabolites in a time- and dose-dependent manner. J Clin Psychopharmacol 20:708\u2013710","journal-title":"J Clin Psychopharmacol"},{"key":"4161_CR9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1744-859X-9-11","volume":"9","author":"T Furuse","year":"2010","unstructured":"Furuse T, Hashimoto K (2010) Fluvoxamine for aripiprazole-associated akathisia in patients with schizophrenia: a potential role of sigma-1 receptors. Ann Gen Psychiatry 9:11","journal-title":"Ann Gen Psychiatry"},{"issue":"Suppl 1","key":"4161_CR10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/00002018-199200071-00007","volume":"7","author":"SL Gerson","year":"1992","unstructured":"Gerson SL, Meltzer H (1992) Mechanisms of clozapine-induced agranulocytosis. Drug Saf Int J Med Toxicol Drug Exp 7(Suppl 1):17\u201325","journal-title":"Drug Saf Int J Med Toxicol Drug Exp"},{"key":"4161_CR11","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/026988110001400212","volume":"14","author":"AJ Goudie","year":"2000","unstructured":"Goudie AJ (2000) What is the clinical significance of the discontinuation syndrome seen with clozapine? J Psychopharmacol 14:188\u2013192","journal-title":"J Psychopharmacol"},{"key":"4161_CR12","unstructured":"GRADE (2015) Grading of Recommendations Assessment, Development and Evaluation. http:\/\/www.essentialevidenceplus.com\/product\/ebm_loe.cfm?show=grade . Accessed 24 Nov 2015"},{"key":"4161_CR13","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/187152709789824633","volume":"8","author":"K Hashimoto","year":"2009","unstructured":"Hashimoto K (2009a) Can the sigma-1 receptor agonist fluvoxamine prevent schizophrenia? CNS Neurol Disord Drug Targets 8:470\u2013474","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"4161_CR14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2174\/1871524910909030197","volume":"9","author":"K Hashimoto","year":"2009","unstructured":"Hashimoto K (2009b) Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. Cent Nerv Syst Agents Med Chem 9:197\u2013204","journal-title":"Cent Nerv Syst Agents Med Chem"},{"key":"4161_CR15","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1023\/A:1008748110692","volume":"21","author":"M Heeringa","year":"1999","unstructured":"Heeringa M, Beurskens R, Schouten W, Verduijn MM (1999) Elevated plasma levels of clozapine after concomitant use of fluvoxamine. Pharm World Sci 21:243\u2013244","journal-title":"Pharm World Sci"},{"key":"4161_CR16","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00004714-199408000-00011","volume":"14","author":"C Hiemke","year":"1994","unstructured":"Hiemke C, Weigmann H, Hartter S, Dahmen N, Wetzel H, Muller H (1994) Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 14:279\u2013281","journal-title":"J Clin Psychopharmacol"},{"key":"4161_CR17","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/00004714-200210000-00010","volume":"22","author":"C Hiemke","year":"2002","unstructured":"Hiemke C, Peled A, Jabarin M, Hadjez J, Weigmann H, Hartter S, Modai I, Ritsner M, Silver H (2002) Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. J Clin Psychopharmacol 22:502\u2013506","journal-title":"J Clin Psychopharmacol"},{"key":"4161_CR18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s002139900351","volume":"149","author":"D Hinze-Selch","year":"2000","unstructured":"Hinze-Selch D, Deuschle M, Weber B, Heuser I, Pollmacher T (2000) Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight. Psychopharmacology 149:163\u2013169","journal-title":"Psychopharmacology"},{"key":"4161_CR19","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/00007691-199408000-00006","volume":"16","author":"M Jerling","year":"1994","unstructured":"Jerling M, Lindstrom L, Bondesson U, Bertilsson L (1994) Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 16:368\u2013374","journal-title":"Ther Drug Monit"},{"key":"4161_CR20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0924-977X(95)00069-2","volume":"6","author":"HJ Koponen","year":"1996","unstructured":"Koponen HJ, Leinonen E, Lepola U (1996) Fluvoxamine increases the clozapine serum levels significantly. Eur Neuropsychopharmacol 6:69\u201371","journal-title":"Eur Neuropsychopharmacol"},{"key":"4161_CR21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pharmthera.2007.05.004","volume":"115","author":"J Lameh","year":"2007","unstructured":"Lameh J, Burstein ES, Taylor E, Weiner DM, Vanover KE, Bonhaus DW (2007) Pharmacology of N-desmethylclozapine. Pharmacol Ther 115:223\u2013231","journal-title":"Pharmacol Ther"},{"key":"4161_CR22","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.mehy.2012.12.024","volume":"80","author":"N Legare","year":"2013","unstructured":"Legare N, Gregoire CA, De Benedictis L, Dumais A (2013) Increasing the clozapine: norclozapine ratio with co-administration of fluvoxamine to enhance efficacy and minimize side effects of clozapine therapy. Med Hypotheses 80:689\u2013691","journal-title":"Med Hypotheses"},{"key":"4161_CR23","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/01.ftd.0000211801.66569.80","volume":"28","author":"SK Lin","year":"2006","unstructured":"Lin SK, Su SF, Pan CH (2006) Higher plasma drug concentration in clozapine-treated schizophrenic patients with side effects of obsessive\/compulsive symptoms. Ther Drug Monit 28:303\u2013307","journal-title":"Ther Drug Monit"},{"key":"4161_CR24","first-page":"81","volume":"182","author":"ML Lu","year":"2003","unstructured":"Lu ML, Lane HY (2003) Adjunctive fluvoxamine with clozapine. Br J Psychiatry J Ment Sci 182:81","journal-title":"Br J Psychiatry J Ment Sci"},{"key":"4161_CR25","doi-asserted-by":"crossref","first-page":"594","DOI":"10.4088\/JCP.v61n0809","volume":"61","author":"ML Lu","year":"2000","unstructured":"Lu ML, Lane HY, Chen KP, Jann MW, Su MH, Chang WH (2000) Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J Clin Psychiatry 61:594\u2013599","journal-title":"J Clin Psychiatry"},{"key":"4161_CR26","doi-asserted-by":"crossref","first-page":"766","DOI":"10.4088\/JCP.v65n0607","volume":"65","author":"ML Lu","year":"2004","unstructured":"Lu ML, Lane HY, Lin SK, Chen KP, Chang WH (2004) Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry 65:766\u2013771","journal-title":"J Clin Psychiatry"},{"key":"4161_CR27","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/00004714-200112000-00005","volume":"21","author":"JM Meyer","year":"2001","unstructured":"Meyer JM (2001) Individual changes in clozapine levels after smoking cessation: results and a predictive model. J Clin Psychopharmacol 21:569\u2013574","journal-title":"J Clin Psychopharmacol"},{"key":"4161_CR28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0014-2999(96)00254-3","volume":"307","author":"N Narita","year":"1996","unstructured":"Narita N, Hashimoto K, Tomitaka S, Minabe Y (1996) Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 307:117\u2013119","journal-title":"Eur J Pharmacol"},{"key":"4161_CR29","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1600-0447.2011.01710.x","volume":"123","author":"J Nielsen","year":"2011","unstructured":"Nielsen J, Damkier P, Lublin H, Taylor D (2011) Optimizing clozapine treatment. Acta Psychiatr Scand 123:411\u2013422","journal-title":"Acta Psychiatr Scand"},{"key":"4161_CR30","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/bdi.12018","volume":"14","author":"J Nielsen","year":"2012","unstructured":"Nielsen J, Kane JM, Correll CU (2012a) Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirror-image study. Bipolar Disord 14:863\u2013869","journal-title":"Bipolar Disord"},{"key":"4161_CR31","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/JCP.0b013e318267b3cd","volume":"32","author":"J Nielsen","year":"2012","unstructured":"Nielsen J, Nielsen RE, Correll CU (2012b) Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study. J Clin Psychopharmacol 32:678\u2013683","journal-title":"J Clin Psychopharmacol"},{"key":"4161_CR32","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.euroneuro.2012.03.003","volume":"22","author":"J Nielsen","year":"2012","unstructured":"Nielsen J, Roge R, Schjerning O, Sorensen HJ, Taylor D (2012c) Geographical and temporal variations in clozapine prescription for schizophrenia. Eur Neuropsychopharmacol 22:818\u2013824","journal-title":"Eur Neuropsychopharmacol"},{"key":"4161_CR33","doi-asserted-by":"crossref","first-page":"603","DOI":"10.4088\/JCP.12r08064","volume":"74","author":"J Nielsen","year":"2013","unstructured":"Nielsen J, Correll CU, Manu P, Kane JM (2013) Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? J Clin Psychiatry 74:603\u2013613, quiz 613","journal-title":"J Clin Psychiatry"},{"key":"4161_CR34","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/070674370204700306","volume":"47","author":"LK Oyewumi","year":"2002","unstructured":"Oyewumi LK, Cernovsky ZZ, Freeman DJ, Streiner DL (2002) Relation of blood counts during clozapine treatment to serum concentrations of clozapine and nor-clozapine. Can J Psychiatry 47:257\u2013261","journal-title":"Can J Psychiatry"},{"key":"4161_CR35","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/00004714-200112000-00011","volume":"21","author":"V Ozdemir","year":"2001","unstructured":"Ozdemir V, Kalow W, Okey AB, Lam MS, Albers LJ, Reist C, Fourie J, Posner P, Collins EJ, Roy R (2001) Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C \u2192 A\u00a0polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. J Clin Psychopharmacol 21:603\u2013607","journal-title":"J Clin Psychopharmacol"},{"key":"4161_CR36","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.schres.2005.07.016","volume":"79","author":"V Peritogiannis","year":"2005","unstructured":"Peritogiannis V, Tsouli S, Pappas D, Mavreas V (2005) Acute effects of clozapine-fluvoxamine combination. Schizophr Res 79:345\u2013346","journal-title":"Schizophr Res"},{"key":"4161_CR37","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00213-005-0248-4","volume":"185","author":"SK Praharaj","year":"2006","unstructured":"Praharaj SK, Arora M, Gandotra S (2006) Clozapine-induced sialorrhea: pathophysiology and management strategies. Psychopharmacology 185:265\u2013273","journal-title":"Psychopharmacology"},{"key":"4161_CR38","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.mehy.2013.11.043","volume":"82","author":"RM Procyshyn","year":"2014","unstructured":"Procyshyn RM, Vila-Rodriguez F, Honer WG, Barr AM (2014) Clozapine administered once versus twice daily: does it make a difference? Med Hypotheses 82:225\u2013228","journal-title":"Med Hypotheses"},{"key":"4161_CR39","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1176\/ajp.155.11.1626f","volume":"155","author":"MS Rahman","year":"1998","unstructured":"Rahman MS, Grace JJ, Pato MT, Priest B (1998) Sertraline in the treatment of clozapine-induced obsessive-compulsive behavior. Am J Psychiatry 155:1629\u20131630","journal-title":"Am J Psychiatry"},{"key":"4161_CR40","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-2004-815525","volume":"37","author":"I Reznik","year":"2004","unstructured":"Reznik I, Yavin I, Stryjer R, Spivak B, Gonen N, Strous R, Mester R, Weizman A, Kotler M (2004) Clozapine in the treatment of obsessive-compulsive symptoms in schizophrenia patients: a case series study. Pharmacopsychiatry 37:52\u201356","journal-title":"Pharmacopsychiatry"},{"key":"4161_CR41","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1527-3458.2001.tb00200.x","volume":"7","author":"H Silver","year":"2001","unstructured":"Silver H (2001) Fluvoxamine as an adjunctive agent in schizophrenia. CNS Drug Rev 7:283\u2013304","journal-title":"CNS Drug Rev"},{"key":"4161_CR42","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/JCP.0b013e3182983d42","volume":"33","author":"H Silver","year":"2013","unstructured":"Silver H, Bilker WB (2013) Add-on fluvoxamine and negative symptoms of schizophrenia: analysis of data from augmentation studies in a single center. J Clin Psychopharmacol 33:710\u2013711","journal-title":"J Clin Psychopharmacol"},{"key":"4161_CR43","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1176\/ajp.152.7.1106","volume":"152","author":"H Silver","year":"1995","unstructured":"Silver H, Kaplan A, Jahjah N (1995) Fluvoxamine augmentation for clozapine-resistant schizophrenia. Am J Psychiatry 152:1098","journal-title":"Am J Psychiatry"},{"key":"4161_CR44","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/0006-3223(96)00170-9","volume":"40","author":"H Silver","year":"1996","unstructured":"Silver H, Kushnir M, Kaplan A (1996) Fluvoxamine augmentation in clozapine-resistant schizophrenia: an open pilot study. Biol Psychiatry 40:671\u2013674","journal-title":"Biol Psychiatry"},{"key":"4161_CR45","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/JCP.0b013e3181acc372","volume":"29","author":"EJ Sirot","year":"2009","unstructured":"Sirot EJ, Knezevic B, Morena GP, Harenberg S, Oneda B, Crettol S, Ansermot N, Baumann P, Eap CB (2009) ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol 29:319\u2013326","journal-title":"J Clin Psychopharmacol"},{"key":"4161_CR46","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1097\/chi.0b013e31812eed10","volume":"46","author":"AL Sporn","year":"2007","unstructured":"Sporn AL, Vermani A, Greenstein DK, Bobb AJ, Spencer EP, Clasen LS, Tossell JW, Stayer CC, Gochman PA, Lenane MC, Rapoport JL, Gogtay N (2007) Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. J Am Acad Child Adolesc Psychiatry 46:1349\u20131356","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"4161_CR47","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00004714-199504000-00012","volume":"15","author":"A Szegedi","year":"1995","unstructured":"Szegedi A, Wiesner J, Hiemke C (1995) Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine. J Clin Psychopharmacol 15:141\u2013143","journal-title":"J Clin Psychopharmacol"},{"key":"4161_CR48","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1055\/s-2007-979221","volume":"32","author":"A Szegedi","year":"1999","unstructured":"Szegedi A, Anghelescu I, Wiesner J, Schlegel S, Weigmann H, Hartter S, Hiemke C, Wetzel H (1999) Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 32:148\u2013153","journal-title":"Pharmacopsychiatry"},{"key":"4161_CR49","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1744-859X-10-26","volume":"10","author":"S Tadokoro","year":"2011","unstructured":"Tadokoro S, Kanahara N, Kikuchi S, Hashimoto K, Masaomi I (2011) Fluvoxamine may prevent onset of psychosis: a case report of a patient at ultra-high risk of psychotic disorder. Ann Gen Psychiatry 10:26","journal-title":"Ann Gen Psychiatry"},{"key":"4161_CR50","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/hup.367","volume":"17","author":"H Takahashi","year":"2002","unstructured":"Takahashi H, Sugita T, Higuchi H, Shimizu T (2002) Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial. Hum Psychopharmacol 17:95\u201398","journal-title":"Hum Psychopharmacol"},{"key":"4161_CR51","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1177\/0091270004266621","volume":"44","author":"CY Wang","year":"2004","unstructured":"Wang CY, Zhang ZJ, Li WB, Zhai YM, Cai ZJ, Weng YZ, Zhu RH, Zhao JP, Zhou HH (2004) The differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers. J Clin Pharmacol 44:785\u2013792","journal-title":"J Clin Pharmacol"},{"key":"4161_CR52","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/00004714-199802000-00002","volume":"18","author":"H Wetzel","year":"1998","unstructured":"Wetzel H, Anghelescu I, Szegedi A, Wiesner J, Weigmann H, Harter S, Hiemke C (1998) Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 18:2\u20139","journal-title":"J Clin Psychopharmacol"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-015-4161-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-015-4161-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-015-4161-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T16:36:53Z","timestamp":1558629413000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-015-4161-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,2]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["4161"],"URL":"https:\/\/doi.org\/10.1007\/s00213-015-4161-1","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,2]]}}}